Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-04-12 @ 11:16 PM
Study NCT ID:
NCT07381959
Status:
RECRUITING
Last Update Posted:
2026-02-02
First Post:
2025-12-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biomarkers of Brain Injury in Children With Brain Tumors
Sponsor:
Uppsala University
Organization:
Study Overview
Official Title:
Biomarkörer för hjärnskada Hos Barn Med hjärntumör
Status:
RECRUITING
Status Verified Date:
2026-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BiomarkCBT
Brief Summary:
The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is:
Can investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors?
Researchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers.
Participants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.
Can investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors?
Researchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers.
Participants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: